secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2022-04-01T23:59:59+00:00
Accession:  0001193125-22-092360
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences enters ATM equity sales agreement for up to $25M
------------------------------------------------------------------

- Agreement with Ladenburg Thalmann allows sale of up to $25M common stock; initial prospectus supplement covers $7M.
- Commission of 3.0% of gross proceeds payable to Ladenburg for at-the-market sales.
- Net proceeds to be used for general corporate purposes and funding of clinical programs.
- Company not obligated to sell any shares; sales will be at prevailing market prices.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312522092360/0001193125-22-092360-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312522092360/d345612d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-092360

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer